{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-011315","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2025-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.604936+00:00","generated_at":"2026-05-27T01:04:32.190259+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cadrenal appoints James J. Ferguson as CMO; Dr. Douglas Losordo departs","bullets":["Dr. Ferguson, over 25 years cardiovascular experience, appointed Chief Medical Officer effective Feb 5, 2025.","Annual base salary of $505,000; discretionary bonus up to 40% of base; option grant of 60,000 shares.","Dr. Losordo separated amicably; severance includes 6-month salary continuation, bonus, and accelerated vesting.","Dr. Ferguson to lead late-stage clinical development of tecarfarin including pivotal LVAD trial.","Compensation includes option vesting: 25% on Mar 1, 2026, balance pro rata over 36 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-011315","json":"https://secwatch.observer/filing/0001213900-25-011315.json","markdown":"https://secwatch.observer/filing/0001213900-25-011315.md","text":"https://secwatch.observer/filing/0001213900-25-011315.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025011315/0001213900-25-011315-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025011315/ea0230166-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T01:04:32.190259+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02c52604f9","claim":"James J. Ferguson III was appointed as Chief Medical Officer at Cadrenal Therapeutics, Inc..","evidence_excerpt":"On February 4, 2025, Cadrenal Therapeutics, Inc. (the “Company”) entered into an employment agreement with James J. Ferguson III (the “Employment Agreement”), effective as of February 5, 2025 (the “Effective Date”), to employ Dr. Ferguson as the Company’s Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025011315/0001213900-25-011315-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"e7d1b3c9e2","claim":"Douglas Losordo was terminated as Chief Medical Officer at Cadrenal Therapeutics, Inc..","evidence_excerpt":"On February 4, 2025, the Company terminated its employment relationship with its Chief Medical Officer, Douglas Losordo, on a mutual amicable basis.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025011315/0001213900-25-011315-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}